Exopharm Ltd. (AU:EX1) has released an update.
Exopharm Ltd., soon to be known as Tryptamine Therapeutics Limited, has announced an update to its share register following a consolidation of capital at a 2.5:1 ratio, as previously detailed and approved by shareholders. The update will see changes in the number of ordinary shares and various options, with updated holding statements dispatched to stakeholders. Trading on a normal basis is set to commence on 24 April 2024, following the issue date of 23 April 2024.
For further insights into AU:EX1 stock, check out TipRanks’ Stock Analysis page.
